Epidermolysis Bullosa Market to Grow at Highest Pace Owing to Increasing Research and Development Activities

The epidermolysis bullosa market comprises therapeutics that are used for the treatment of epidermolysis bullosa disease. Epidermolysis bullosa is a group of rare genetic disorders that cause easy blistering of the skin and mucous membranes. The major symptoms of epidermolysis bullosa include blistering, skin scarring, and fragility that may impact multiple internal organs. Currently, there are no definitive cure available for this disease and management mainly focuses on wound care, pain relief, and prevention of complications. The key therapeutics used in the treatment of epidermolysis bullosa include wound care management products, drugs, and gene therapy.

The global epidermolysis bullosa market is estimated to be valued at US$ 3,429.30 Mn in 2024 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the epidermolysis bullosa are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. Amryt Pharma leads the market with its drug Filsuvez which has received approval by the FDA for treatment of dystrophic and junctional epidermolysis bullosa.

The key factor fueling the growth of epidermolysis bullosa market is rising prevalence of the disease along with growing awareness about available therapeutics. According to studies, around 1 in every 50,000 people worldwide are affected by some form of epidermolysis bullosa.

Advancements in gene therapy and development of novel therapeutic candidates are also expected to drive the market growth during the forecast period. Several companies are conducting clinical trials evaluating efficacy of gene therapies in correcting genetic defects causing epidermolysis bullosa.

Market Trends

Growing research collaborations to develop innovative therapies - Leading market players are collaborating with research institutes to support research activities and clinical development of novel treatment options. For instance, Amryt entered partnership with the EB Research Partnership to support further research in EB therapeutics.

Increasing focus on gene therapies - Gene therapy is considered as one of the most promising approaches to cure epidermolysis bullosa. Several biopharma companies are conducting clinical trials evaluating efficacy and safety of various gene therapy candidates.

Market Opportunities

Late-stage clinical pipeline provides major growth opportunities - Drugs like camsirubicin (Krystal Biotech) and AB-101 (Abeona Therapeutics) are currently under late-stage clinical trials evaluating their efficacy in EB. Successful approval and commercialization will drive significant revenues in coming years.

Untapped emerging markets - Majority of current EB treatments are available only in developed nations. Emerging nations in Asia Pacific and Latin America provide significant opportunities due to growing healthcare investments and increasing EB patient population.

Impact of COVID-19 on Epidermolysis Bullosa Market Growth

The COVID-19 pandemic has significantly impacted the growth of the Epidermolysis Bullosa market. During the initial outbreak, the market witnessed declining growth due to lockdowns imposed across major countries. This led to disruptions in manufacturing and supply chain activities. The pandemic also negatively impacted the healthcare industry's funding for research and development activities. However, with economic activities restarting post lockdowns, the market is projected to recover steadily over the coming years.

The Epidermolysis Bullosa treatment demand increased during the pandemic as patients needed ongoing care. However, hospital resources were redirected to handle growing COVID-19 cases. Telehealth and digital health solutions emerged as a preferred mode of care delivery during this period. Market players also focused on ensuring adequate supply of existing treatment medications. Governments and healthcare organizations allocated additional funds to develop novel therapies and drugs to address the ongoing unmet needs in Epidermolysis Bullosa treatment.

Epidermolysis Bullosa Market in North America

The North America region holds the highest value share in the global Epidermolysis Bullosa market, primarily driven by the United States. This can be attributed to the presence of advanced healthcare facilities, growing research funding for orphan diseases, increasing patient diagnosis rates, rising physician awareness, and rapid uptake of novel therapy products within the country.

Moreover, favorable reimbursement policies ensure affordability of high-cost treatment regimens. Additionally, medical device and pharmaceutical companies also actively invest in the US EB market for drug development and commercialization of therapeutic solutions. Key market players collaborate with research institutes and patient advocacy groups to understand unmet needs and expedite the regulatory approval process. These factors support the dominance of the North America region in the global Epidermolysis Bullosa treatment market.

Epidermolysis Bullosa Market in Asia Pacific

The Asia Pacific region demonstrates the fastest growth rate for the Epidermolysis Bullosa market over the forecast period from 2023 to 2030. This strong market growth can be attributed to the improving healthcare infrastructure across developing nations. There is a significant rise in healthcare expenditure by various Asian governments to strengthen medical facilities. This enhances access to advanced diagnostic technologies and therapies.

Additionally, the region also witnesses medical tourism growth, attracting patients from Western countries to avail high-quality yet affordable treatment. Supportive regulatory guidelines also help expedite the launch of novel EB drugs. Furthermore, increasing disease prevalence rates due to growing elderly population base generate substantial treatment demand. The rapidly expanding biotechnology and pharmaceutical industries also attract sizable investments for research and commercialization of orphan drugs. These factors will continue to drive the Asia Pacific market's rapid growth through 2030.